Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20439975 | 0.84 | HTR2C (0.44) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL23735310 | 0.82 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL19406882 | 0.82 | PNMT (0.46) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL21509795 | 0.81 | HTR2A (0.37) | PNMTHTR2AHTR2C | |
| SCHEMBL15503204 | 0.81 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL20909785 | 0.81 | PNMT (0.58) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL19684582 | 0.81 | PNMT (0.44) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL19684576 | 0.81 | PNMT (0.53) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL15503117 | 0.81 | PNMT (0.44) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL19684577 | 0.81 | PNMT (0.50) | PNMTHTR2AHTR2CADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219504-A1 | MACROCYCLIC TLR7 AGONIST, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Visonpharma Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885HTR2A 4697/4885HTR2C 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.